Eerste faciliteit in de regio die klinische opslag, verpakking en distributie aanbiedt, zal banengroei stimuleren
PHILADELPHIA–(BUSINESS WIRE)– PCI Pharma Services (PCI), een toonaangevende wereldwijde organisatie voor contractontwikkeling en productie (CDMO), heeft vandaag de opening aangekondigd van haar Clinical Services Centre of Excellence in Bridgewater, MA, de eerste faciliteit in zijn soort die ondersteuning biedt de groeiende behoeften van wereldwijde ontwikkelaars van biologische geneesmiddelen in de regio New England. De nieuwe faciliteit zal meer flexibiliteit en schaalbaarheid bieden voor secundaire verpakking, distributie en koudeketenopslag van innovatieve therapieën in ontwikkeling.
“Terwijl de noordoostelijke biofarmaceutische markt blijft groeien, brengen we onderscheidende klinische leveringsmogelijkheden naar de achtertuin van productontwikkeling, waardoor een gepersonaliseerde en responsieve benadering van veranderende klantbehoeften ontstaat”, aldus Salim Haffar, CEO, PCI Pharma Services. “Deze nieuwste faciliteit volgt onze groei in faciliteiten in Berlijn, Duitsland en Rockford, Illinois, en zal een aanzienlijk lokaal banengroeipotentieel creëren.”
PCI Pharma Services Opens New England Center of Excellence to Bring Global Clinical Supply Capabilities to New England
First Facility in the Region to Offer Clinical Storage, Packaging and Distribution Will Fuel Job Growth
PHILADELPHIA–(BUSINESS WIRE)– PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, the first facility of its kind to support the growing needs of global developers of biologics in the New England region. The new facility will provide increased flexibility and scalability for secondary packaging, distribution and cold chain storage of innovative therapies in development.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005234/en/
Rendering of the new PCI facility in Bridgewater, MA. (Photo: Business Wire)
“As the northeast biopharma market continues to grow, we are bringing distinctive clinical supply capabilities to the backyard of product development, creating a personalized and responsive approach to evolving client needs,” said Salim Haffar, CEO, PCI Pharma Services. “This newest facility follows our growth in facilities in Berlin, Germany, and Rockford, Illinois, and will create significant local job growth potential.”
To keep pace with the growth in biologics and gene therapies, which require cold chain infrastructure including deep freeze, the new facility has a capacity for a -20°C freezer, 35 ultra-low temperature freezers at -80°C and 12 liquid nitrogen freezers. The Center of Excellence also features a temperature-controlled room containing a 5,000 square foot cooler at 2° to 8°C, each with five levels of warehouse racking. A 1000-square-foot cold secondary packaging room will eventually be converted to primary packaging with the planned construction of an additional secondary packing unit.
“Boston is a booming biotech market with hundreds of local organizations developing new compounds in the biologics space,” said Craig LaMarca, General Manager of Boston Clinical Trial Services, PCI Pharma Services. “The facility features leading technologies and capabilities, making it a crucial component to help our clients deliver life-saving therapies to patients safely and efficiently.”
PCI currently occupies 50,000 square feet of the new 100,000 square foot building, with the remaining space available for lease. The campus was constructed to reflect Environmental Social Governance (ESG) and sustainability efforts. These features include a complex stormwater runoff system with a series of ponds that filter the water before it leaves the site, an underground oil and sedimentation separation tank, electric vehicle chargers and the exclusive use of LED lighting throughout the building.
The opening of the New England Center of Excellence marks the latest in a series of worldwide expansions for PCI including six sites across three continents, including Bedford, New Hampshire; Berlin, Germany; San Diego, California; Rockford, Illinois; and Melbourne, Australia. In February 2022, PCI sites in San Diego and Melbourne added innovative equipment with aseptic fill-finish capabilities to enhance PCI’s global offerings and deliver much-needed capacity to early-phase clinical clients.
For more information on PCI’s aseptic fill-finish and lyophilization capabilities, please click here.
About PCI Pharma Services
PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.
Ty Guzman-Touchberry, WE Communications
email@example.com / +1-212-551-4877